CSL Ltd Annual Report 2021

11. Legacy Equity Programs The following table provides information on the key characteristics of the legacy programs on foot during the 2021 reporting period. The 2018 (granted October 2017), 2019 (granted September 2018) and 2020 (granted September 2019) PSU LTI awards have the same key characteristics as the 2021 award disclosed in section 3.2.5. Key Characteristics of Prior Financial Year Performance Right and Option Grants Feature 2017 Grant Date 1 October 2016 (reported 2017/expiry 30 Sep 2021) Instrument Options and Performance Rights Tranches One tranche of Options and three tranches of Performance Rights Performance Period Four years Performance Measure Options – individual performance measure Performance Rights T1 – relative TSR (rTSR) against selected global Pharmaceutical and Biotechnology companies, and T2 and T3 – EPS growth (EPSg) Vesting Schedule Tranche 1 – rTSR < 50th %ile – 0% vesting 50th %ile – 50% vesting Between 50th and 75th %ile – Straight line vesting from 50% to 100% vesting ≥ 75th %ile – 100% vesting Tranche 2 – EPS target performance < 8% – 0% vesting 8% to 13% – Straight line vesting from 35% to 100% vesting 13% – 100% vesting Tranche 3 – EPS maximum performance 13% – 0% vesting 13% to 15% – Straight line vesting from 0% to 100% vesting 15% – 100% vesting Exercise Price Options only: A$107.25 Retesting No retest CSL Limited Annual Report 2020/21 104 Directors’ Report